• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TCT 2013: St. Jude Medical’s Portico valve looks good at 30 days

TCT 2013: St. Jude Medical’s Portico valve looks good at 30 days

October 29, 2013 By Arezu Sarvestani

TCT 2013: St. Jude Medical's Portico valve looks good in new sizes

Minnesota medical device maker St. Jude Medical (NYSE:STJ) this week released results from clinical trials of its 23 mm and 25 mm Portico transcatheter aortic valve implantation devices, touting patient health improvements and low adverse events at 30 days.

The Portico system aims to address challenges discovered with early generations of TAVI technology, including difficulty getting the cardiac implants positioned accurately, valve leakage and heart block development that requires permanent pacemaker implantation, among other issues. The device can be fully re-sheathed into its delivery catheter during the procedure, allowing a cardiologist to reposition the device or retrieve it entirely.

Lead investigator Dr. Ganesh Manoharan presented 1-month results from the Portico CE study of 84 patients, reporting a 3.6% mortality rate, 2.4% major stroke rate, 10.8% pacemaker implantation rate and 10.8% major bleeding rate, results that Manoharan referred to as "an excellent safety profile."

"St. Jude Medical has a long history of developing world class heart valve technologies. Today’s positive results speak to our capability and commitment to bring meaningful advancements to patients with heart valve disease," company cardiovascular & ablation technologies president Frank Callaghan said in prepared remarks.

The study was initiated to evaluate the 23 mm Portico valve, which last year won CE Mark approval in the European Union, and the trial was expanded to include the 25 mm valve, which is currently under regulatory review.

St. Jude is pretty far behind its rival medtech giants in terms of getting a TAVI device on the market, following Edwards Lifesciences’ (NYSE:EW) FDA-approved Sapien system and Medtronic’s (NYSE:MDT) CoreValve, which is slated to hit the U.S. market next year.

TAVI systems have gotten a lot of attention at this year’s TCT conference, where researchers discussed the cost-effectiveness of extending the procedure to lower-risk patients, Medtronic delved deeper into 1-year “real-world” clinical results for its CoreValve system, and researchers pitted CoreValve and Sapien against one another, finding few differences outside of a higher pacemaker implantation rate for CoreValve.

Filed Under: News Well, Replacement Heart Valves Tagged With: Clinical Trials, Conference coverage, Minnesota, stjudemedical, Transcatheter Cardiovascular Therapeutics symposium (TCT)

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy